Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
about
Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.Use of prescription drug claims data to identify lipid-lowering medication exposure in pharmacoepidemiology studies: potential pitfalls.Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort studyPredictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.Influencers of generic drug utilization: A systematic review.Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013.Primary non-adherence and the new-user design.Injection Testosterone and Adverse Cardiovascular Events: A Case-crossover Analysis.
P2860
Q30974376-31EF3048-9A3C-4248-BD17-E22F579EDCBBQ31049668-CBFB4364-24E3-4499-9934-1BED45F22980Q31060524-7DE00996-840F-4A70-A762-74AF652C2D0CQ31090652-E2270040-36F4-44FE-B0CF-13E4BD990CBFQ31102987-4C7A65A9-CE5E-45F7-9C2B-D2F4DAA91335Q35235448-A197DC51-DB3E-46E1-A87F-6A4E13EA9B9AQ35824855-2CAF0268-41F9-424D-9EDE-55661F170EC2Q36085794-206F0AD4-3CE9-41D2-9EF5-0678920713B2Q36571742-0B384043-DF96-4FDB-85F8-378476F66896Q36576444-F9801A83-990E-44AE-8F99-70143F1871F1Q37066166-CDF20A28-3801-45A0-BF47-4326C6C3A9FAQ38621600-08D01E8B-0EA9-4CEA-B32C-080C8E1A398AQ39983483-07F5D359-2373-4042-A86E-FCB54E1013E8Q49822791-3F689E6C-C03C-4616-AD18-A48C3719F5A9Q49985009-F68A494D-2DA1-4252-BB50-3F36059B6998
P2860
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@ast
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@en
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@nl
type
label
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@ast
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@en
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@nl
prefLabel
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@ast
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@en
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@nl
P2860
P1433
P1476
Evidence of sample use among new users of statins: implications for pharmacoepidemiology.
@en
P2093
Xiaojuan Li
P2860
P304
P356
10.1097/MLR.0000000000000174
P577
2014-09-01T00:00:00Z